Perte de poids non-GLP-1

At a Glance

Overview

The Basics

Non-GLP-1 weight loss is not one mechanism. This collection exists because the same broad user intent pulls together five very different routes: satiety tools that do not directly use GLP-1 agonism, monoamine appetite suppressants, GH-axis or body-composition agents, mitochondrial or metabolic-efficiency compounds, and convenience blends sold into the same vendor ecosystem.

That means the page works best as a mechanism map rather than a stack.

cagrilintide and oxytocin occupy the satiety lane, but in very different ways. tesofensine occupies the stimulant and monoamine lane. tesamorelin, aod-9604, and adipotide occupy the GH-axis and body-composition lane, though their clinical maturity differs sharply. 5-amino-1mq, mots-c, and slu-pp-332 occupy the mitochondrial and metabolic lane. lipo-c, lemon, slu-pp-332-5-amino, and slu-pp-332-orforglipron occupy the blend lane.

Several listed members are not peptides at all. 5-amino-1mq, tesofensine, slu-pp-332, and orforglipron are small molecules. lipo-c and lemon are blend slugs with thin local documentation. The collection title therefore reflects function and site taxonomy more than chemistry.

The Science

The satiety lane is defined by intake and reward control. cagrilintide acts through amylin biology with meaningful appetite and gastric-emptying effects. oxytocin touches appetite through hypothalamic and stress-regulation pathways, but its weight-loss identity is secondary to its broader neuroendocrine role.

The stimulant and monoamine lane is defined by central neurotransmission. tesofensine increases dopamine, norepinephrine, and serotonin signaling, which reduces appetite, reduces food noise, and slightly raises energy expenditure. That is a much more CNS-heavy intervention style than the peptide-centered satiety lane.

The GH-axis and body-composition lane is defined by partitioning and fat-depot behavior. tesamorelin improves visceral-fat handling through physiologic GH and IGF-1 signaling. aod-9604 leans toward lipolysis without broad GH-axis spillover. adipotide is a more radical adipose-vasculature concept that lives mostly as a preclinical proof of principle.

The mitochondrial and metabolic lane is defined by substrate handling and energy use. 5-amino-1mq works through NNMT and NAD-linked metabolism. mots-c works through ATIC, AICAR, and AMPK-linked adaptation. slu-pp-332 works through ERR agonism and exercise-mimetic transcriptional effects.

The blend lane is the least evidence-secure part of the page. lipo-c, lemon, slu-pp-332-5-amino, and slu-pp-332-orforglipron are catalog shapes, not cleanly documented independent mechanisms in the local peptide KB.

How It Works / Synergy Analysis

The Basics

The cleanest way to interpret this collection is by lane rather than by product count.

The satiety lane reduces intake or food preoccupation. The monoamine lane reduces appetite by changing central neurotransmission. The GH-axis and body-composition lane changes partitioning, trunk fat, or fat-cell behavior. The mitochondrial and metabolic lane pushes fuel selection, oxidation, and energy expenditure. The blend lane packages one or more of those ideas into a convenience SKU.

That structure matters because real synergy is narrow, while normalized stacking is broad and usually unsupported.

The Science

The clearest genuine synergy sits between distinct, non-duplicative mechanisms. tesamorelin can coexist conceptually with metabolic-support compounds because it addresses visceral fat and recomposition rather than appetite. 5-amino-1mq, mots-c, and slu-pp-332 all fit the same broad metabolic lane, but they are not redundant at the molecular level: NNMT, AMPK-linked mitochondrial signaling, and ERR agonism are different entry points.

cagrilintide presents a special case. It belongs on a non-GLP-1 function page because it is not itself a GLP-1 agonist. But the strongest real-world combination story in its KB is still GLP-1-adjacent. That means the page should acknowledge true combo logic without letting the collection drift into custom incretin protocol language.

tesofensine does not create simple “complementary lane” logic just because it uses monoamines instead of peptides. Appetite suppression, reduced food noise, insomnia, anxiety, and heart-rate elevation all travel together in that mechanism. The presence of a different pathway is not a free pass for combination use.

The blend lane needs the hardest boundary. slu-pp-332-5-amino is mechanistically coherent at the component level, but that still falls short of validating the combined SKU. slu-pp-332-orforglipron is even less clean because it blends a non-peptide GLP-1 small molecule into a non-GLP-1 collection. lipo-c and lemon remain under-documented in the local peptide KB, so convenience is the only defensible claim.

Key Benefits & Goals

The Basics

This collection supports five broad weight-loss conversations:

• stronger satiety and quieter food noise
• stimulant-like appetite suppression with some added metabolic drive
• better visceral-fat targeting and recomposition
• better fuel selection, fat oxidation, and metabolic flexibility
• blend-level convenience for people shopping by category rather than mechanism

Those are adjacent goals, but they are not the same question.

The Science

The strongest benefits inside this collection are:

• appetite suppression and food-noise control from cagrilintide and tesofensine
• central-adiposity and body-composition improvement from tesamorelin
• modest metabolic or satiety support from oxytocin
• metabolic-flexibility and fat-oxidation logic from 5-amino-1mq, mots-c, and slu-pp-332
• lower-yield lipolysis support from aod-9604

The weaker or more speculative goals are:

• major standalone obesity efficacy from aod-9604, adipotide, mots-c, 5-amino-1mq, or slu-pp-332
• assuming that blend SKUs carry stronger evidence than their component theories
• assuming that non-GLP-1 automatically means lower-risk or easier stacking

Evidence Summary

The Basics

The evidence base here is uneven by design.

tesamorelin has the strongest clinical footing in the collection, but for a narrow visceral-fat indication rather than general obesity. tesofensine has strong Phase 2 efficacy for a non-GLP-1 oral agent, but with clear cardiovascular and psychiatric caution. cagrilintide is real obesity pharmacology, yet its strongest practical narrative overlaps the GLP-1 ecosystem. oxytocin has meaningful metabolic research signals, but it is not primarily a weight-loss compound.

The metabolic lane is where the evidence thins out quickly. 5-amino-1mq, mots-c, and slu-pp-332 are mechanistically interesting and commercially visible, but the human-outcome base is still limited or absent. adipotide remains more historical than contemporary. aod-9604 is safer but low-ceiling.

The Science

Evidence calibration across this collection:

• Strongest approved or clinically anchored body-composition member: tesamorelin
• Strongest non-GLP-1 oral appetite-suppression signal: tesofensine
• Moderate obesity-pharmacology satiety member with GLP-1-adjacent combo gravity: cagrilintide
• Secondary, context-limited metabolic member: oxytocin
• Low-to-moderate, modest-effect body-composition member: aod-9604
• Proof-of-concept or preclinical metabolic members: 5-amino-1mq, mots-c, slu-pp-332, adipotide
• Underdocumented blend members: lipo-c, lemon, slu-pp-332-5-amino, slu-pp-332-orforglipron

That hierarchy matters because the collection becomes misleading when every member is described as equally established.

Component Highlights

Quick links: 5-Amino-1MQ, AOD-9604, Adipotide, Cagrilintide, Lemon, Lipo-C, MOTS-C, Oxytocin, SLU-PP-332, SLU-PP-332 + 5-Amino, SLU-PP-332 + Orforglipron, Tesamorelin, Tesofensine.

5-Amino-1MQ

5-Amino-1MQ is a non-peptide metabolic member built around NNMT inhibition, NAD preservation, and adipocyte reprogramming. The mechanistic story is cleaner than the human evidence base.

AOD-9604

AOD-9604 is the low-ceiling body-composition member. Its appeal is selective lipolysis support without full GH-axis baggage, but its human efficacy signal remains modest.

Adipotide

Adipotide is the harshest experimental member on the page. It attacks adipose tissue through vascular targeting rather than appetite, satiety, or mitochondrial signaling, and its modern relevance is limited by safety and thin translational confidence.

Cagrilintide

Cagrilintide is the strongest satiety-specific member in the collection. It deserves real attention for food-noise and intake control, while also carrying the clearest warning that its most mature combo story points back toward GLP-1 territory.

Lemon

Lemon is a registry-listed blend slug with no standalone local peptide KB guide. It belongs in the taxonomy lane, not in the evidence-rich mechanism lane.

Lipo-C

Lipo-C is also a registry-listed blend slug without a standalone local peptide KB guide. Local related-guide references tie it to injectable L-carnitine and lipotropic support, but the page should keep that characterization narrow.

MOTS-C

MOTS-C is the mitochondrial-derived metabolic-signal member. It fits exercise-mimetic, endurance, and substrate-partitioning conversations better than appetite or classical obesity pharmacology.

Oxytocin

Oxytocin is the neuroendocrine wildcard. It has real appetite and metabolic signals, but those signals sit beside social, anxiolytic, and context-dependent effects rather than replacing dedicated obesity pharmacology.

SLU-PP-332

SLU-PP-332 is the ERR-driven exercise-mimetic member. It is a small molecule, not a peptide, and its metabolic promise currently sits ahead of its human evidence.

SLU-PP-332 + 5-Amino

SLU-PP-332 + 5-Amino is a blend expression of the metabolic lane. The component logic is clear enough to describe, but the blend itself is not validated by the local KB.

SLU-PP-332 + Orforglipron

SLU-PP-332 + Orforglipron is the taxonomy-problem blend. One half is an ERR agonist and the other half is a non-peptide GLP-1 small molecule, so it does not fit a pure non-GLP-1 story despite living in this site category.

Tesamorelin

Tesamorelin is the visceral-fat and recomposition specialist. It is the most clinically grounded member in the collection and the clearest example of weight-loss-adjacent benefit that is not really about appetite.

Tesofensine

Tesofensine is the monoamine appetite-suppression specialist. It offers some of the strongest non-GLP-1 weight-loss efficacy on the page and some of the most obvious insomnia, mood, and heart-rate trade-offs.

Comparative Analysis

The Basics

The shortest useful interpretation of the collection is:

• cagrilintide = satiety-first obesity pharmacology
• oxytocin = secondary satiety and stress-eating modulation
• tesofensine = stimulant / monoamine appetite suppression
• tesamorelin = visceral-fat and recomposition specialist
• aod-9604 = low-yield lipolysis adjunct
• adipotide = proof-of-concept adipose-targeting outlier
• 5-amino-1mq, mots-c, slu-pp-332 = metabolic-efficiency lane
• lipo-c, lemon, and the pre-mixed SLU blends = convenience lane

That framing is more accurate than treating the collection as thirteen versions of the same intervention idea.

The Science

The cleanest comparison framework is:

• For strongest non-GLP-1 appetite and food-noise suppression: tesofensine, then cagrilintide
• For visceral-fat targeting and recomposition: tesamorelin
• For milder fat-mobilization support with better tolerability: aod-9604
• For metabolic-flexibility and energy-expenditure framing: 5-amino-1mq, mots-c, slu-pp-332
• For secondary appetite or stress-eating support: oxytocin
• For blend convenience rather than mechanism clarity: lipo-c, lemon, slu-pp-332-5-amino, slu-pp-332-orforglipron

The key non-overlap is:

• the satiety lane changes intake
• the monoamine lane changes reward and arousal
• the GH-axis lane changes body composition and fat distribution
• the metabolic lane changes substrate handling and energy use
• the blend lane changes packaging, not necessarily evidence quality

Getting Started

The Basics

This collection works best when the first question is functional lane, not product count.

Appetite-dominant conversations cluster around cagrilintide, tesofensine, and sometimes oxytocin. Trunk-fat and recomposition conversations cluster around tesamorelin and, at a lower-confidence level, aod-9604. Energy-expenditure and metabolic-flexibility conversations cluster around 5-amino-1mq, mots-c, and slu-pp-332. Blend slugs belong last in the interpretation order because packaging does not clarify mechanism.

The Science

The page is strongest when it keeps these distinctions intact:

• food-noise suppression is not the same thing as fat oxidation
• visceral-fat reduction is not the same thing as scale-weight suppression
• exercise-mimetic signaling is not the same thing as stimulant appetite control
• blend availability is not the same thing as combination validation

That framing keeps the page educational rather than protocol-like.

General Dosing Considerations

The Basics

This collection is not a shared dosing template.

The members span oral small molecules, injectable peptides, intranasal hormone use, research compounds with no human PK, and blend SKUs whose exact composition is not documented in the local peptide KB. Those are different dosing worlds.

The Science

The main dose-framing differences are:

• tesofensine uses low-dose oral monoamine pharmacology with long half-life and cardiovascular monitoring
• tesamorelin uses daily injectable GH-axis stimulation with IGF-1 implications
• cagrilintide uses weekly satiety pharmacology with steep GI and fatigue sensitivity
• mots-c and slu-pp-332 carry unusually high protocol uncertainty relative to their evidence base
• oxytocin depends strongly on route and receptor desensitization management
• the blend lane should not be read as a dosing shortcut

What to Expect

The Basics

The early signal depends on lane.

Satiety members tend to show reduced appetite, reduced food noise, or GI burden. Monoamine members tend to show appetite suppression mixed with sleep and mood effects. GH-axis or body-composition members tend to show waistline and recomposition changes more than dramatic appetite change. Metabolic-lane members tend to show energy, endurance, heat, or subtle recomp narratives before obvious weight loss.

The Science

Rough response patterns across the collection:

• Days to 2 weeks: appetite and food-noise shifts from cagrilintide, tesofensine, and sometimes oxytocin
• Weeks 2-6: clearer body-composition or waist effects from tesamorelin; early tolerance judgment for aod-9604
• Weeks 4-8: energy, endurance, and recomp signal sorting for 5-amino-1mq, mots-c, and slu-pp-332
• Longer horizons: blend-lane attribution remains weak because component separation is poor

The key nuance is that not every member is trying to move the same metric.

Safety & Interactions

The Basics

The biggest risk in this collection is false equivalence.

tesofensine carries stimulant-like insomnia, mood, and heart-rate risk. cagrilintide carries GI and fatigue burden. tesamorelin carries IGF-1, edema, and fluid-retention considerations. oxytocin carries receptor-desensitization, mood-context, pregnancy, and hyponatremia concerns. adipotide carries renal concern. mots-c, slu-pp-332, and 5-amino-1mq remain underpowered by human data.

The Science

The strongest collection-level cautions are:

• 5-amino-1mq, tesofensine, slu-pp-332, and orforglipron are not peptides
• tesofensine should not be treated like a casual appetite add-on because monoamine effects also drive insomnia, anxiety, irritability, and heart-rate changes
• cagrilintide belongs in the satiety lane, but its dominant real-world stacking pattern overlaps GLP-1 use and should not be normalized on this page
• tesamorelin is body-composition specific and monitoring-heavy rather than broadly appetite suppressive
• slu-pp-332-orforglipron is not a pure non-GLP-1 concept because orforglipron is a GLP-1 receptor agonist
• lipo-c and lemon do not have enough local peptide KB depth to justify strong safety or efficacy claims beyond generic caution

The cleanest editorial rule is:

• compare lanes first
• separate real mechanism complementarity from protocol normalization
• keep blend members explicitly below standalone evidence-backed members

Frequently Asked Questions

Is this actually a peptide-only collection?

No. Several members are not peptides, and the collection should say that repeatedly. The title reflects site taxonomy and function, not strict chemistry.

Why is cagrilintide here if the strongest combo story is with GLP-1 therapy?

Because cagrilintide itself is not a GLP-1 agonist and it remains relevant to appetite and food-noise control. The page still needs to state that its best-developed combination narrative is GLP-1-adjacent.

Why does a non-GLP-1 collection include SLU-PP-332 + Orforglipron?

Because the site registry includes that blend slug inside this category. The taxonomy is mixed. The guide should state clearly that orforglipron is a non-peptide GLP-1 agonist and that the blend is not a clean non-GLP-1 example.

Are Lemon and Lipo-C well-documented weight-loss members in the local peptide KB?

No. They exist as live site slugs, but the local peptide docs do not contain standalone KB guides for them. The evidence language should remain conservative.

Does this page support combining multiple lanes into one protocol?

No. The page maps mechanisms and trade-offs. It does not validate a whole-collection stack.

Which members carry the strongest practical weight-loss signal?

tesamorelin is the strongest clinically grounded body-composition member, tesofensine is the strongest monoamine appetite-suppression member, and cagrilintide is the strongest satiety member on the page.

Related Guides

Quick links: 5-Amino-1MQ, AOD-9604, Adipotide, Cagrilintide, Lemon, Lipo-C, MOTS-C, Oxytocin, SLU-PP-332, SLU-PP-332 + 5-Amino, SLU-PP-332 + Orforglipron, Tesamorelin, Tesofensine, Orforglipron, Semaglutide, Tirzepatide, Retatrutide, NAD+.

Members of This Collection

• 5-Amino-1MQ
• AOD-9604
• Adipotide
• Cagrilintide
• Lemon
• Lipo-C
• MOTS-C
• Oxytocin
• SLU-PP-332
• SLU-PP-332 + 5-Amino
• SLU-PP-332 + Orforglipron
• Tesamorelin
• Tesofensine